Navigation Links
Boston Scientific Announces $1.0B Share Repurchase Program
Date:7/28/2011

ng statements include, among other things, statements regarding our financial performance, including profitability; our business prospects; regulatory compliance; the strength of our balance sheet; our capacity to generate cash flow; and our share repurchase programs.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; the market for our products, including the U.S. CRM market;  expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights and related and other litigation; financial market conditions; and our restructuring initiatives; integration of acquired companies; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may updat
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised
2. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
3. Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results
4. Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
5. Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System
6. Boston Scientific Welcomes Passage of Patent Reform Bill
7. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
8. Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter
9. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
10. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
11. Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Nov. 29 AIDS Action Council,joins organizations and individuals ... 20th annual World AIDS Day, December 1, 2007. Since ... awareness,about the HIV/AIDS pandemic and to reinvigorate global, national, ... and 2008 theme of World AIDS Day is leadership. ...
Cached Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:7/11/2014)... Latham, New York (PRWEB) July 11, 2014 ... imaging as an integral part of each patient’s unique ... detailed analysis of the skin’s health and trouble areas ... a personalized aesthetic plan to be established. , Vectra ... during the consultation appointment, Vectra 3D uses a quick ...
(Date:7/11/2014)... Canada (PRWEB) July 11, 2014 ... redefines email management with its unique Netmail Platform, ... Microsoft’s World Partner Conference (WPC), which will be ... from July 13-17, 2014. During the show, Netmail ... an email management solution that consolidates email security, ...
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
(Date:7/10/2014)... Washington, D.C. (PRWEB) July 10, 2014 ... Alliance for Bangladesh Worker Safety announced today it will ... up to four months’ wages for workers displaced as ... , To date, Alliance inspections have resulted in the ... found in all five cases, raising immediate safety concerns. ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
Breaking Medicine News(10 mins):Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2
... An implantable hemodynamic monitor (IHM) may help to ... with heart failurethose with diastolic heart failure (DHF), reports ... Failure ( http://www.onlinejcf.com/ ), published by Elsevier. , ... of South Carolina, Charleston, the researchers analyzed data on ...
... and aim to strengthen science in selected member states ... EMBC Member States hosting the grantees finance the grants ... Croatia, the Czech Republic, Estonia, Hungary, Poland, Portugal and ... three to five years to help them establish their ...
... of Employees Covered by Plans in Multiple States, Lockheed ... Vantage to Identify Local-Level Opportunities , ... HealthLeaders-InterStudy , the leading provider of managed care ... to coast, Lockheed Martin works with carriers across the ...
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... 11 Barr Pharmaceuticals, Inc. (NYSE: ... and Drug Administration (FDA) has accepted for review ... Live Oral Vaccines Biologics License Application (BLA). These ... initiative and demonstrate the Company,s ability to develop, ...
... the emotional health implications of cosmetic surgery are still ... as The Oprah Magazine and Cosmopolitan ... overall worthwhile option for enhancing physical appearance and emotional ... published in Women,s Health Issues journal, is ...
Cached Medicine News:Health News:Implantable monitor may help in managing diastolic heart failure 2Health News:Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities 2Health News:Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities 3Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 2Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 4Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 5Health News:Women's magazines downplay emotional health risks of cosmetic surgery: UBC study 2
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes....
... tips in a rack for single- ... of Autoclavable Racks: Can be steam ... in racks with an 8 x ... tips is specifically designed to ensure ...
RNase-free Tips...
... tips in a rack for single- ... of Autoclavable Racks: Can be steam ... in racks with an 8 x ... tips is specifically designed to ensure ...
Medicine Products: